Depletion of Cytosolic Phospholipase A2 in Bone Marrow-derived Macrophages Protects Against Lung Cancer Progression and Metastasis

Overview

Journal Cancer Res

Specialty Oncology

Date 2009 Feb 12

PMID 19208832

Citations 32

Authors

Mary C M Weiser-Evans

Xue-Qing Wang

Jay Amin

Vicki Van Putten

Rashmi Choudhary

Robert A Winn

Robert Scheinman

Peter Simpson

Mark W Geraci

Raphael A Nemenoff

Affiliations

Soon will be listed here.

Abstract

Cancer progression and metastasis involves interactions between tumor cells and the tumor microenvironment (TME). We reported that mice deficient for cytosolic phospholipase A(2) (cPLA(2)-KO) are protected against the development of lung tumors. The goal of this study was to examine the role of cPLA(2) in the TME. Mouse lung cancer cells (CMT167 and Lewis lung carcinoma cells) injected directly into lungs of syngeneic mice formed a primary tumor, and then metastasized to other lobes of the lung and to the mediastinal lymph nodes. Identical cells injected into cPLA(2)-KO mice showed a dramatic decrease in the numbers of secondary metastatic tumors. This was associated with decreased macrophage staining surrounding the tumor. Wild-type mice transplanted with cPLA(2)-KO bone marrow had a marked survival advantage after inoculation with tumor cells compared with mice receiving wild-type (WT) bone marrow. In vitro, coculturing CMT167 cells with bone marrow-derived macrophages from WT mice increased production of interleukin 6 (IL-6) by cancer cells. This increase was blocked in cocultures using cPLA(2)-KO macrophages. Correspondingly, IL-6 staining was decreased in tumors grown in cPLA(2)-KO mice. These data suggest that stromal cPLA(2) plays a critical role in tumor progression by altering tumor-macrophage interactions and cytokine production.

Citing Articles

Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database.

Contreras-Salinas H, Romero-Lopez M, Olvera-Montano O, Rodriguez-Herrera L BMJ Open Ophthalmol. 2024; 9(1).

PMID: 39209740 PMC: 11367404. DOI: 10.1136/bmjophth-2024-001764.

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity.

Kleczko E, Hinz T, Nguyen T, Gurule N, Navarro A, Le A NPJ Precis Oncol. 2023; 7(1):15.

PMID: 36739466 PMC: 9899278. DOI: 10.1038/s41698-023-00355-2.

Upregulation of complement proteins in lung cancer cells mediates tumor progression.

Kleczko E, Poczobutt J, Navarro A, Laskowski J, Johnson A, Korpela S Front Oncol. 2023; 12:1045690.

PMID: 36686777 PMC: 9849673. DOI: 10.3389/fonc.2022.1045690.

Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response.

Kleczko E, Le A, Hinz T, Nguyen T, Navarro A, Hu C Cancer Lett. 2023; 556:216062.

PMID: 36657561 PMC: 10544803. DOI: 10.1016/j.canlet.2023.216062.

Association between use of antacid medications (proton pump inhibitors and histamine-2 receptor antagonists) and the incidence of lung cancer: A population-based cohort analysis.

Go S, Lee D, Choi W, Jeong J Medicine (Baltimore). 2022; 101(36):e30399.

PMID: 36086741 PMC: 10980457. DOI: 10.1097/MD.0000000000030399.

References

Bonventre J, Huang Z, Taheri M, OLeary E, Li E, Moskowitz M . Reduced fertility and postischaemic brain injury in mice deficient in cytosolic phospholipase A2. Nature. 1997; 390(6660):622-5. DOI: 10.1038/37635. View

Meyer A, Dwyer-Nield L, Hurteau G, Keith R, Ouyang Y, Freed B . Attenuation of the pulmonary inflammatory response following butylated hydroxytoluene treatment of cytosolic phospholipase A2 null mice. Am J Physiol Lung Cell Mol Physiol. 2006; 290(6):L1260-6. DOI: 10.1152/ajplung.00182.2005. View

Welsh T, Green R, Richardson D, Waller D, OByrne K, Bradding P . Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol. 2005; 23(35):8959-67. DOI: 10.1200/JCO.2005.01.4910. View

Lewis C, Pollard J . Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006; 66(2):605-12. DOI: 10.1158/0008-5472.CAN-05-4005. View

Harizi H, Gualde N . Pivotal role of PGE2 and IL-10 in the cross-regulation of dendritic cell-derived inflammatory mediators. Cell Mol Immunol. 2006; 3(4):271-7. View

Meyer A, Dwyer-Nield L, Hurteau G, Keith R, OLeary E, You M . Decreased lung tumorigenesis in mice genetically deficient in cytosolic phospholipase A2. Carcinogenesis. 2004; 25(8):1517-24. DOI: 10.1093/carcin/bgh150. View

Chen X, Su Y, Fingleton B, Acuff H, Matrisian L, Zent R . An orthotopic model of lung cancer to analyze primary and metastatic NSCLC growth in integrin alpha1-null mice. Clin Exp Metastasis. 2005; 22(2):185-93. DOI: 10.1007/s10585-005-7453-8. View

Sinha P, Clements V, Bunt S, Albelda S, Ostrand-Rosenberg S . Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol. 2007; 179(2):977-83. DOI: 10.4049/jimmunol.179.2.977. View

Layton M, FRANKS L . Heterogeneity in a spontaneous mouse lung carcinoma: selection and characterisation of stable metastatic variants. Br J Cancer. 1984; 49(4):415-21. PMC: 1976760. DOI: 10.1038/bjc.1984.67. View

10.

Riches D, Henson P, Remigio L, Catterall J, Strunk R . Differential regulation of gene expression during macrophage activation with a polyribonucleotide. The role of endogenously derived IFN. J Immunol. 1988; 141(1):180-8. View

11.

Riedl K, Krysan K, Pold M, Dalwadi H, Heuze-Vourch N, Dohadwala M . Multifaceted roles of cyclooxygenase-2 in lung cancer. Drug Resist Updat. 2004; 7(3):169-84. DOI: 10.1016/j.drup.2004.04.003. View

12.

Kenny P, Lee G, Bissell M . Targeting the tumor microenvironment. Front Biosci. 2007; 12:3468-74. PMC: 2841020. DOI: 10.2741/2327. View

13.

Naugler W, Karin M . The wolf in sheep's clothing: the role of interleukin-6 in immunity, inflammation and cancer. Trends Mol Med. 2008; 14(3):109-19. DOI: 10.1016/j.molmed.2007.12.007. View

14.

Condeelis J, Pollard J . Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124(2):263-6. DOI: 10.1016/j.cell.2006.01.007. View

15.

Onn A, Isobe T, Itasaka S, Wu W, OReilly M, Hong W . Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res. 2003; 9(15):5532-9. View

16.

Harris S, Padilla J, Koumas L, Ray D, Phipps R . Prostaglandins as modulators of immunity. Trends Immunol. 2002; 23(3):144-50. DOI: 10.1016/s1471-4906(01)02154-8. View

17.

Heasley L, Thaler S, Nicks M, Price B, Skorecki K, Nemenoff R . Induction of cytosolic phospholipase A2 by oncogenic Ras in human non-small cell lung cancer. J Biol Chem. 1997; 272(23):14501-4. DOI: 10.1074/jbc.272.23.14501. View

18.

Han C, Demetris A, Stolz D, Xu L, Lim K, Wu T . Modulation of Stat3 activation by the cytosolic phospholipase A2alpha and cyclooxygenase-2-controlled prostaglandin E2 signaling pathway. J Biol Chem. 2006; 281(34):24831-46. DOI: 10.1074/jbc.M602201200. View

19.

Hagemann T, Wilson J, Burke F, Kulbe H, Li N, Pluddemann A . Ovarian cancer cells polarize macrophages toward a tumor-associated phenotype. J Immunol. 2006; 176(8):5023-32. DOI: 10.4049/jimmunol.176.8.5023. View

20.

Ancrile B, Lim K, Counter C . Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev. 2007; 21(14):1714-9. PMC: 1920165. DOI: 10.1101/gad.1549407. View